

## What prescribers need to know about ATTAIN™

### Why prescribe ATTAIN™?

- ATTAIN™ is a patent pending topical application.
- Topical products can decrease systemic side-effects.
- Affordable for the patient (average cost is \$.75 per day).
- Side-effects are minimized due to being topical
- All individual products (active and non-active ingredients) are FDA approved and have USP monographs
- Convenient daily application (after first 12 weeks).
- Non-Greasy
- It WORKS!

### **ATTAIN™ Topical Hair Formula Product for Men with androgenic alopecia (AGA or male-pattern baldness).**

#### Active Ingredients:

- Active Ingredients in ATTAIN™ Hair For Men- topical formula:
  - Finasteride and dutasteride
    - The 2  $5\alpha$ -reductase inhibitors (5ARIs), dutasteride and finasteride, suppress dihydrotestosterone (DHT) by inhibiting the conversion of testosterone to DHT. Finasteride inhibits only the Type 2 5AR isoenzyme, whereas dutasteride, the only dual 5ARI, selectively inhibits both Type 1 and Type 2 5AR isoenzymes. Hence dutasteride may provide added benefit since it inhibits both type 1 and 2 isoenzymes. \
  - Azelaic Acid
    - a regulator of Gli1 and Gli2 genes and it can protect bulge cells from UVB damage. Studies show that azelaic acid in combination with minoxidil promotes hair growth via induction of Shh protein expression in the hair follicles
  - Caffeine
    - The caffeine-induced inhibition of PDE enzymes increases intracellular cAMP concentrations, resulting in stimulatory effects on cell metabolism and proliferation. Hence, caffeine has a high potential to be beneficial in subjects suffering from hair loss that originates from premature termination of the hair growth phase.
  - Minoxidil
    - shortens telogen, accelerates telogen-exogen phase and causes the premature entry of resting hair follicles into anagen phase. Moreover, minoxidil increases hair follicle size. A large part of hair treatment scientific literature confirms the efficacy of topically applied minoxidil in humans. In particular, patients treated with minoxidil showed a significant increase in "non vellus" hair count starting from baseline.
  - Proprietary and unique silicone base
    - Hypo-allergenic
    - Provides long-lasting moisturization
    - protecting the skin's barrier and reducing water loss
    - Promotes a soothing and nurturing environment

- Rich in skin-friendly fatty acids and lipids

ATTAIN™ Topical Hair Formula Product for **Women** with androgenic alopecia (AGA or male-pattern baldness). For Post-Menopausal Age Group

Active Ingredients:

- Finasteride
  - evaluated for hair growth in women, especially in the postmenopausal-aged group, and those wishing to avoid systemic side effects.
- Dutasteride- See above
- Minoxidil- See Above
- Azelaic Acid- See Above
- Caffeine- See Above
- Progesterone
  - Progesterone can influence hair follicle growth through a locally acting mechanism of action at the level of the hair follicle, progesterone decreases the conversion of testosterone to dihydrotestosterone (through the inhibition of 5-alpha reductase activity).

ATTAIN™ Topical Hair Formula Product for **Women** with androgenic alopecia (AGA or male-pattern baldness). For Pre-Menopausal Age Group

- Minoxidil- See Above for explanation
- Azelaic Acid- See Above for explanation
- Caffeine- See Above for explanation
- Progesterone- See Above for explanation
  
- What to tell patients:
  - Rinse hands after application
  - For external use only
  - Apply at least once per day, twice per day is advised for the first 12 weeks.
  - Transference is possible if hands are not washed or if someone touches the scalp after application.
  - Apply adequate amount to balding areas of scalp twice a day for 12 weeks then may decrease to once per day. Best if applied to damp scalp after a warm shower.
  - Applicator will deliver 0.5 Grams of product for each actuation. Most people need 1 to 2 Grams per application.

How to prescribe: See attached template

CORNER DRUGS & COMPOUNDING CENTER  
430 N. 3<sup>rd</sup> Ave  
Chatsworth GA  
706-695-0444  
Fax: 855-710-7228

## FAX

### Attain™ (patent pending) Hair Growth Formula

---

Patient: \_\_\_\_\_ PHONE# \_\_\_\_\_

DATE OF BIRTH \_\_\_\_\_

ADDRESS \_\_\_\_\_

R<sub>x</sub>:

Check one

For Men

Minoxidil 15%, Azelaic Acid 0.325% , Finasteride 0.02%, Dutasteride 0.02%,  
Caffeine 3%

For Women (post-menopausal)

Minoxidil 15%, Azelaic Acid 0.325% , Finasteride 0.01%, Dutasteride 0.01%,  
Caffeine 3%, Progesterone 0.025%

For Women (pre-menopausal)

Minoxidil 15%, Azelaic Acid 0.325% , Caffeine 3%, Progesterone 0.025%

Apply adequate amount to balding areas of scalp twice a day for 12 weeks then may decrease to once per day. Best if applied to damp scalp after a warm shower.

#75 gm \_\_\_\_\_ Refills

Auth by \_\_\_\_\_ Date \_\_\_\_\_  
*SIGNATURE*

PRESCRIBER NAME \_\_\_\_\_  
*If prescriber is NP or PA, please indicate your Supervising Physician \_\_\_\_\_*

NPI# \_\_\_\_\_

Address \_\_\_\_\_  
Street City State Zip Code

References:

[Genetic variations associated with response to dutasteride in the treatment of male subjects with androgenetic alopecia](#)

Arang Rhie, Ho-Young Son, Soo Jung Kwak, Seungbok Lee, Dong Young Kim, Bark-Lynn Lew, Woo-Young Sim, Jeong-Sun Seo, Ohsang Kwon, Jong-Il Kim, Seong Jin Jo  
PLoS One. 2019; 14(9): e0222533. Published online 2019 Sep 16. doi: 10.1371/journal.pone.0222533

[The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis](#)

Zhongbao Zhou, Shiqiang Song, Zhenli Gao, Jitao Wu, Jiajia Ma, Yuanshan Cui  
Clin Interv Aging. 2019; 14: 399–406. Published online 2019 Feb 20. doi: 10.2147/CIA.S192435  
PMCID: PMC6388756

[Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date](#)

Wimolsiri Iamsungang, Kanchana Leerunyakul, Poonkiat Suchonwanit  
Drug Des Devel Ther. 2020; 14: 951–959. Published online 2020 Mar 2. doi: 10.2147/DDDT.S240615  
PMCID: PMC7060023

[Azelaic acid stimulates catalase activation and promotes hair growth through upregulation of Gli1 and Gli2 mRNA and Shh protein](#)

[Elham Amirfakhryan](#), [Behzad Davarnia](#), [Farhad Jeddi](#), and [Nowruz Najafzadeh](#)  
[Avicenna J Phytomed.](#) 2020 Sep-Oct; 10(5): 460–471.  
PMCID: PMC7508322 PMID: [32995324](#)

Review Article: Caffeine and Its Pharmacological Benefits in the Management of Androgenetic Alopecia: A Review Völker J.M. · Koch N. · Becker M.Klenk A. Skin Pharmacol Physiol 2020;33:153–169 <https://doi.org/10.1159/000508228>

The use of minoxidil in the treatment of male and female androgenetic alopecia: a story of more than 30 years

Review

G Ital Dermatol Venereol. 2018 Feb;153(1):102-106.  
doi: 10.23736/S0392-0488.17.05781-9.

[Mauro Barbareschi](#)

PMID: 29319278

[Int J Mol Sci.](#) 2020 Aug; 21(15): 5342.

Published online 2020 Jul 28. doi: [10.3390/ijms21155342](https://doi.org/10.3390/ijms21155342)

PMCID: PMC7432488

PMID: [32731328](#)

Hormonal Effects on Hair Follicles

[Monika Grymowicz](#), [Ewa Rudnicka](#), [Agnieszka Podfigurna](#), [Paulina Napierala](#), [Roman Smolarczyk](#), [Katarzyna Smolarczyk](#), and [Blazej Meczekalski](#)